Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
SLU-PP-332 is a synthetic small-molecule pan-ERR agonist studied for estrogen-related receptor signaling, skeletal muscle metabolism, mitochondrial respiration, fatty acid oxidation, energy expenditure and exercise-mimetic transcriptional programs. This 2026 research guide explains what SLU-PP-332 is, how ERRα, ERRβ and ERRγ signaling works, why the compound is studied in metabolic and mitochondrial models, how it differs from peptide-based metabolic compounds, and what quality, documentation, storage and research-use-only standards matter when evaluating this newer compound.
SLU-PP-332 is a synthetic pan estrogen-related receptor agonist studied for activation of ERRα, ERRβ and ERRγ, with strong interest in ERRα-linked skeletal muscle metabolism. In published preclinical research, SLU-PP-332 has been studied for exercise-mimetic transcriptional signaling, mitochondrial respiration, fatty acid oxidation, energy expenditure, metabolic syndrome models, heart failure models and age-related muscle or mitochondrial dysfunction models. SLU-PP-332 is not a peptide and should be described as a research-use-only small molecule, not as a supplement, exercise replacement, fat-loss product or human-use compound.
SLU-PP-332 is one of the most discussed newer compounds in exercise-mimetic and metabolic research. It is not a peptide. It is a synthetic small molecule designed to activate estrogen-related receptors, also known as ERRs, which are orphan nuclear receptors involved in energy metabolism, mitochondrial function, oxidative phosphorylation and skeletal muscle gene-expression programs.
SLU-PP-332 is studied because it can activate ERR pathways that are normally involved in exercise-related metabolic adaptation. In research models, those pathways connect to mitochondrial respiration, fatty acid oxidation, energy expenditure and muscle metabolic programming.
Because SLU-PP-332 is often called an “exercise mimetic” in scientific literature, claim discipline is important. That term describes a research mechanism in controlled preclinical models. It does not mean the compound replaces exercise, produces guaranteed fat loss, treats metabolic disease or is appropriate for human use.
SLU-PP-332 is a synthetic research compound developed as an agonist of estrogen-related receptors. ERRs are nuclear receptors that regulate transcriptional programs involved in mitochondrial function, oxidative metabolism, skeletal muscle energetics and fatty acid handling.
| Feature | SLU-PP-332 Detail | Research Interpretation |
|---|---|---|
| Common name | SLU-PP-332 | Primary compound name used in research and supplier literature. |
| Compound type | Synthetic small molecule | Not a peptide, even though it is often grouped near metabolic research products. |
| CAS number | 303760-60-3 | Common registry number used for compound identification. |
| Molecular formula | C18H14N2O2 | Useful for identity confirmation and chemical documentation. |
| Primary target family | Estrogen-related receptors, ERRα, ERRβ and ERRγ | Supports its classification as a pan-ERR agonist research compound. |
| Major research context | Exercise-mimetic signaling and mitochondrial metabolism | Studied for ERR-dependent transcriptional programs involved in oxidative metabolism. |
| Research-use status | Laboratory research only | Not for human consumption, veterinary use, diagnostic use, therapeutic use, supplement use or performance use. |
The central research mechanism of SLU-PP-332 involves activation of estrogen-related receptors. ERRs are orphan nuclear receptors that regulate transcriptional networks connected to mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and skeletal muscle energetics.
| Pathway Component | Research Role | Why It Matters for SLU-PP-332 |
|---|---|---|
| ERRα | Major metabolic nuclear receptor involved in oxidative metabolism and mitochondrial function. | SLU-PP-332 has been reported to show strong activity at ERRα, making this a key pathway for interpretation. |
| ERRβ | Related ERR family receptor involved in transcriptional regulation and energy biology. | Contributes to the compound’s pan-ERR research profile. |
| ERRγ | ERR family receptor linked to oxidative metabolism, cardiac tissue and mitochondrial gene expression. | Relevant to cardiac, skeletal muscle and mitochondrial pathway models. |
| PGC-1α-related networks | Co-regulatory pathways involved in mitochondrial biogenesis and exercise adaptation. | ERR activity is often studied in relation to PGC-1α-linked metabolic programs. |
| Mitochondrial respiration | Cellular oxygen use and oxidative energy production. | A key experimental readout in skeletal muscle and metabolic cell models. |
| Fatty acid oxidation | Metabolic pathway for using fatty acids as fuel. | Frequently discussed in SLU-PP-332 metabolic research and exercise-mimetic models. |
SLU-PP-332 has been studied most often in preclinical metabolic, mitochondrial, skeletal muscle, heart failure, kidney aging and exercise-mimetic pathway models.
| Research Area | What Is Being Studied | Important Limitation |
|---|---|---|
| Exercise-mimetic signaling | ERR-dependent transcriptional programs resembling parts of exercise-induced metabolic adaptation. | Exercise-mimetic research does not mean the compound replaces exercise or produces human performance outcomes. |
| Skeletal muscle metabolism | Mitochondrial respiration, oxidative gene expression, endurance-related transcription and fatty acid oxidation. | Preclinical muscle findings should not be converted into athletic-performance claims. |
| Metabolic syndrome models | Energy expenditure, fat mass, fatty acid oxidation, insulin sensitivity and whole-body metabolic outcomes in animal models. | Animal-model results should not be generalized into human weight-loss or disease-treatment claims. |
| Cardiac research | Heart failure models, mitochondrial function, fibrosis markers and fatty acid metabolism gene programs. | Cardiac research should not be converted into heart-health or therapeutic claims. |
| Kidney and aging research | Age-related mitochondrial dysfunction, inflammation and renal metabolic changes in preclinical models. | Aging-model findings should remain experimental and not become anti-aging claims. |
| Analytical and metabolism research | In vitro metabolism, detection, characterization and structure-activity relationship development for pan-ERR agonists. | Analytical studies support identification and research development, not consumer-use claims. |
SLU-PP-332 is often grouped with metabolic or mitochondrial research compounds, but its mechanism is distinct because it targets ERR nuclear receptor signaling rather than peptide receptors, mitochondrial membranes, cofactors or nutrient transport systems.
| Compound | Primary Research Pathway | How It Differs From SLU-PP-332 |
|---|---|---|
| SLU-PP-332 | ERRα, ERRβ, ERRγ nuclear receptor agonism | Small-molecule transcriptional regulator studied for exercise-mimetic and mitochondrial metabolic gene programs. |
| MOTS-C | Mitochondrial-derived peptide and metabolic signaling | A peptide studied for metabolic homeostasis and stress-response signaling, not ERR nuclear receptor agonism. |
| SS-31 | Mitochondrial membrane, cardiolipin and oxidative stress pathways | A mitochondria-targeting peptide focused on membrane and oxidative-stress biology. |
| L-Carnitine | Carnitine shuttle and fatty acid transport | A fatty-acid transport compound, not a nuclear receptor agonist. |
| NAD+ | Cellular redox biology and mitochondrial cofactor pathways | A cellular cofactor involved in redox reactions, not an ERR agonist. |
| 5-Amino-1MQ | NNMT inhibition and adipocyte metabolism | A small molecule studied through NNMT and adipocyte signaling, not pan-ERR activation. |
| Retatrutide and Tirzepatide | Incretin receptor pathway research | Peptide receptor agonists affecting GLP-1, GIP and glucagon pathways, not ERR nuclear receptor signaling. |
SLU-PP-332 activates ERR nuclear receptors. MOTS-C and SS-31 are mitochondrial peptides. L-Carnitine helps fatty acid transport. NAD+ supports redox biology. 5-Amino-1MQ targets NNMT. Retatrutide and tirzepatide activate incretin receptors. These are all metabolic research categories, but they are not the same mechanism.
SLU-PP-332 has an emerging research literature focused on ERR agonism, exercise-mimetic biology, metabolic syndrome models, cardiac models, aging-related mitochondrial dysfunction and analytical characterization.
| Evidence Area | What the Literature Reports | Research Interpretation |
|---|---|---|
| ERR pan-agonism | Foundational studies identified SLU-PP-332 as a synthetic ERRα, ERRβ and ERRγ agonist with strong ERRα activity. | Supports its classification as a pan-ERR agonist research compound. |
| Exercise-mimetic response | Research reported ERRα-dependent acute aerobic exercise-like transcriptional responses and enhanced exercise capacity in preclinical models. | Mechanistic exercise-mimetic findings should not be converted into human performance claims. |
| Metabolic syndrome models | Preclinical studies reported increased energy expenditure, increased fatty acid oxidation and improved metabolic markers in animal models. | Animal data should not be generalized into human fat-loss or metabolic-disease claims. |
| Heart failure models | ERR agonists including SLU-PP-332 have been studied in pressure-overload heart failure models with changes in cardiac metabolism and survival-related outcomes. | Cardiac model data should remain experimental and not therapeutic. |
| Aging and mitochondrial dysfunction | Emerging studies discuss SLU-PP-332 in age-related skeletal muscle, kidney and mitochondrial dysfunction models. | Aging model findings should not be turned into anti-aging claims. |
| Analytical characterization | Recent work has examined in vitro metabolism, detection and structure-activity relationship development for SLU-PP-332 and related pan-ERR agonists. | Supports identity, metabolism and next-generation compound development research. |
SLU-PP-332 is often discussed because of its exercise-mimetic research profile, but that term requires careful interpretation. It describes partial activation of exercise-associated molecular pathways in controlled models, not a complete recreation of exercise physiology.
The strongest scientific framing is conservative: SLU-PP-332 is a synthetic pan-ERR agonist used to study nuclear receptor regulation of mitochondrial metabolism, fatty acid oxidation, energy expenditure and exercise-associated transcriptional programs.
Because SLU-PP-332 is a newer small-molecule research compound, quality evaluation should focus on compound identity, purity, lot-level traceability, analytical method, storage guidance and clear research-use-only labeling.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects the material to lot-level analytical documentation. |
| Identity confirmation | Supports confirmation that the material is SLU-PP-332 and not a related ERR agonist or analogue. |
| Purity verification | Supports cleaner interpretation and reduces impurity-related confounding. |
| Clear compound naming | Reduces confusion between SLU-PP-332, newer SLU-PP analogues and other ERR modulators. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and handling variability. |
| Research-use-only labeling | Keeps the material separated from consumer, supplement, therapeutic, exercise, weight-loss or human-use positioning. |
These answers cover the most common SLU-PP-332, ERR agonist, exercise-mimetic and mitochondrial metabolism research questions in 2026.
SLU-PP-332 is a synthetic small-molecule pan-ERR agonist studied for activation of estrogen-related receptors ERRα, ERRβ and ERRγ. It is used in laboratory research involving mitochondrial metabolism, fatty acid oxidation, energy expenditure and exercise-mimetic transcriptional signaling.
No. SLU-PP-332 is not a peptide. It is a synthetic small molecule. It is sometimes discussed near peptide research compounds because it is relevant to metabolic and mitochondrial research.
The common CAS number for SLU-PP-332 is 303760-60-3. Researchers should verify compound identity, purity, molecular reference information and supplier documentation when comparing materials.
SLU-PP-332 is studied as an agonist of estrogen-related receptors, including ERRα, ERRβ and ERRγ. These nuclear receptors regulate gene-expression programs linked to mitochondrial and oxidative metabolism.
SLU-PP-332 is described as an exercise-mimetic compound in some research because it activates ERR-dependent transcriptional programs involved in exercise-related metabolic adaptation. This does not mean it replaces exercise or produces guaranteed human outcomes.
SLU-PP-332 is studied for ERR agonism, mitochondrial respiration, fatty acid oxidation, skeletal muscle metabolism, energy expenditure, exercise-mimetic signaling, metabolic syndrome models, heart failure models and age-related mitochondrial dysfunction models.
SLU-PP-332 should not be described as a direct fat-loss compound. It has been studied in preclinical energy expenditure, fatty acid oxidation and metabolic syndrome models, but research findings should not be turned into consumer weight-loss claims.
SLU-PP-332 is a small-molecule ERR agonist. MOTS-C is a mitochondrial-derived peptide studied for metabolic signaling, while SS-31 is a mitochondria-targeting peptide studied for cardiolipin and oxidative-stress pathways.
No. Luxara Labs SLU-PP-332 is supplied strictly for laboratory research use only. It is not intended for human consumption, veterinary use, diagnostic use, therapeutic use, supplement use, exercise use or cosmetic use.
Luxara Labs carries SLU-PP-332 as a research-use-only compound. The product page is available at https://luxaralabs.com/product/slu-pp-332/.
These references support the SLU-PP-332, ERR agonist, exercise-mimetic, mitochondrial metabolism, fatty acid oxidation, heart failure, aging, analytical chemistry and research-use context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
